BioCentury | Sep 12, 2016
Clinical News

TXA709 regulatory update

...FDA granted Qualified Infectious Disease Product (QIDP) designation to TXA709 from Taxis to treat acute bacterial...
...inhibitor to enter the clinic in 2Q17. Taxis Pharmaceuticals Inc. , North Brunswick, N.J. Product: TXA709...
BioCentury | Sep 28, 2015
Clinical News

Taxis Pharmaceuticals preclinical data

...Taxis said oral TXA709 plus cefdinir showed synergistic activity against all MRSA strains tested in a...
...Agents and Chemotherapy and International Congress of Chemotherapy and Infection joint meeting in San Diego. TXA709...
...S. aureus cell division protein FtsZ inhibitor. Taxis Pharmaceuticals Inc. , North Brunswick, N.J. Product: TXA709...
BioCentury | Jun 4, 2015
Translation in Brief

If it FtsZ

...oral bioavailability. Taxis produced a series of derivatives that improved both properties. The lead compound TXA709...
...bioavailability of 95% and a half-life of 2.66 hours compared with 0.56 hours for PC190723. TXA709...
...a mouse model of systemic methicillin-resistant S. aureus (MRSA)-induced peritonitis infection, all mice treated with TXA709...
Items per page:
1 - 3 of 3